radiomedix.com
Open in
urlscan Pro
23.227.38.65
Public Scan
Submitted URL: http://radiomedix.com/
Effective URL: https://radiomedix.com/
Submission: On December 28 via api from US — Scanned from CA
Effective URL: https://radiomedix.com/
Submission: On December 28 via api from US — Scanned from CA
Form analysis
4 forms found in the DOMGET /search
<form action="/search" method="get" class="search-bar" role="search">
<input type="hidden" name="type" value="product">
<input type="search" name="q" value="" placeholder="Search all products..." aria-label="Search all products...">
<button type="submit" class="search-bar--submit icon-fallback-text">
<span class="icon icon-search" aria-hidden="true"></span>
<span class="fallback-text">Search</span>
</button>
</form>
GET /search
<form action="/search" method="get" class="search-bar" role="search">
<input type="hidden" name="type" value="product">
<input type="search" name="q" value="" placeholder="Search all products..." aria-label="Search all products...">
<button type="submit" class="search-bar--submit icon-fallback-text">
<span class="icon icon-search" aria-hidden="true"></span>
<span class="fallback-text">Search</span>
</button>
</form>
POST /contact#contact_form
<form method="post" action="/contact#contact_form" id="contact_form" accept-charset="UTF-8" class="contact-form"><input type="hidden" name="form_type" value="customer"><input type="hidden" name="utf8" value="✓">
<input type="hidden" name="contact[tags]" value="newsletter">
<div class="input-group">
<label for="Email" class="visually-hidden">Email</label>
<input type="email" value="" placeholder="Email Address" name="contact[email]" id="Email" class="input-group-field" aria-label="Email Address" autocorrect="off" autocapitalize="off">
<span class="input-group-btn">
<button type="submit" class="btn-secondary btn--small" name="commit" id="subscribe">Sign Up</button>
</span>
</div>
</form>
<form id="cwsCallforPriceForm">
<label for="cname" id="cname_label"></label><input type="text" name="cname" id="cname">
<br>
<label for="cemail" id="cemail_label"></label><input type="text" name="cemail" id="cemail"><br>
<label for="cphone" id="cphone_label"></label><input type="text" name="phone" id="phone"><br>
<label for="ccomment" id="ccomment_label"></label><textarea name="comment" cols="5" rows="3" id="comment"></textarea><br>
<input onclick="return false;" type="submit" name="cwsCFPsubmit" id="cwsCFPsubmit" class="btn" value="" style="color:#fff; background-color:black">
</form>
Text Content
Search Cart 0 Menu Cart 0 Search * Home * About Us * Management Team * Advisory Board * Career Opportunities * Services * Drug Discovery * Pre-Clinical * Investigational New Drug Manufacturing * Analytical Services * Commercial Scale Manufacturing * Products * Generators * Radiolabeling Synthesizers * Consumables * Radioisotopes * Precursors * Pipeline * News & Media * News * Publications * Press Releases * Contact * Home * About Us * Management Team * Advisory Board * Career Opportunities * Services * Drug Discovery * Pre-Clinical * Investigational New Drug Manufacturing * Analytical Services * Commercial Scale Manufacturing * Products * Generators * Radiolabeling Synthesizers * Consumables * Radioisotopes * Precursors * Pipeline * News & Media * News * Publications * Press Releases * Contact * CHANGING THE NUCLEAR MEDICINE LANDSCAPE F R O M I N N O V A T I O N T O I N T E R V E N T I O N WHO WE ARE RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is developing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals. RadioMedix has also established 21 CFR 211 compliant contract service facilities for academic and industrial partners: Full cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing of the radiopharmaceuticals, in addition to small animal Molecular Imaging Center for the pre-clinical evaluation of new targets in vitro and in vivo. DISCOVER OUR CAPABILITIES RadioMedix offers a multitude of services. Our bench to bedside capabilities include drug candidate selection, optimization of the drug formulation, evaluation of in vitro and in vivo studies in relevant disease models and a multitude of other preclinical services. When it comes to clinical trials, our team of scientists are prepared to meet your manufacturing needs including radiochemistry solutions, analytical method developments, process validation, manufacturing and testing under GMP guidelines. DISCOVER OUR PIPELINE At Radiomedix, We utilize targeted radionuclide treatment to diagnose and treat patients. This theranostic approach allows for diagnosing patient maladies with precision and control of disease. DISCOVER LATEST NEWS RADIOMEDIX ANNOUNCES A $40 MILLION SERIES A FINANCING FOR THE ADVANCEMENT OF NOVEL TARGETED ALPHA THERAPY RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic... RADIOMEDIX AND ORANO MED ANNOUNCE THE INITIATION OF THE PHASE II MULTI-CENTER CLINICAL TRIAL OF ALPHAMEDIX™ FOR TARGETED ALPHA-EMITTER THERAPY OF NEUROENDOCRINE CANCERS Houston, TX and Plano, TX, Jan. 03, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Orano Med are pleased to announce the... RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Phase Direct to Phase... QUICK LINKS * Home * About Us * Services * Products * Pipeline * News & Media * Contact NEWSLETTER Email Sign Up * Search * Integrity and Compliance -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- * © 2022 RadioMedix * Powered by Shopify * choosing a selection results in a full page refresh × × Please Wait...